Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Block for ME/CFS
NCT05664711Phase 1Completed
- Sponsor
- Neuroversion
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bupivacaine in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), sponsored by Neuroversion. Primary endpoints: Change in Subjective Rating of Symptoms and Change in Cognitive Function. Started Mar 2023; status: completed.
02
Drugs
bupivacaine
03
Conditions
myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Beyond the preview
Go deeper on NCT05664711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664711.